BioPharma Resources

NDA 221291 · Bayer Healthcare

Sunharbo

Asundexian · Film Coated

NovelPriority review

CDER novel approval, Nov 9, 2026: To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Nov 9, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

2 Phase 3, 0 recruiting

FAERS reports

6

6 serious, 0 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 9, 2026.

Sunharbo is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack (TIA). SUNHARBO is a factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack (TIA).

Mechanism: Asundexian is an inhibitor of activated factor XI (FXIa). FXIa leads to downstream activation of Factor X, resulting in thrombin generation via the intrinsic pathway. Thrombin activates Factor XI via a positive feedback loop, which leads to an amplification of thrombus formation and stability. FXIa inhibition reduces amplification of thrombin generation.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 9, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLetter
1 products under this application
  • SUNHARBO · ASUNDEXIAN 50MG · TABLET, FILM COATED · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Asundexian" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • upper gastrointestinal haemorrhage3
  • abdominal pain2
  • pancreatitis necrotising2
  • splenic vein thrombosis2
  • colon cancer1
  • duodenal ulcer haemorrhage1
  • lower gastrointestinal haemorrhage1
  • procedural complication1
  • procedural haemorrhage1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20231
20242
20253

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.